Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus - Uchida,K.; Kigoshi,T.; Nakano,S. (Clin Ther, 1995)